Wedbush Reiterates Outperform Rating On Abiomed

According to Wedbush, Abiomed ABMD Outperform rating is reiterated. Wedbush said that it is adjusting its fiscal Q1:2012 revenues lower to better reflect the expected evolution of the market later this year and be more inline with management comments about the projected split of revenues for the fiscal year between H1 and H2. “We have adjusted our model accordingly, lowering our Q1:12 revenue estimate to $28.5 million from $29.8 million. The end result is a roughly one quarter delay to our prior expected inflection point for increasing Impella revenue sales.” Abiomed closed yesterday at $16.20.